ArriVent BioPharma, Inc.(AVBP)
$11.26+0.36 (+3.30%)
AVBP
ArriVent BioPharma, Inc. financials statements
$11.26
At close:+0.36 (+3.30%)
Want to see AVBP full AI Analyst Report?
ArriVent BioPharma, Inc. (AVBP) Ratios
100 Followers
ArriVent BioPharma, Inc. Ratios
AVBP's free cash flow for Q3 2026 was $-40.71M. For the 2026 fiscal year, AVBP's free cash flow was increased by $0.00 and operating cash flow was $-40.71M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Quick Ratio | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Cash Ratio | 1.76 | 4.30 | 12.94 | 19.54 | 20.51 |
| Solvency Ratio | -6.41 | -4.66 | -5.88 | 0.00 | -28.39 |
| Operating Cash Flow Ratio | -6.19 | -4.06 | -4.80 | -5.22 | -6.92 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 306.95M | $ 209.69M | $ 148.17M | $ 174.25M | $ 41.13M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.07 | 1.08 | 1.05 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.27 | 0.92 | 2.01 | 0.00 | 0.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 93.68% | 85.35% | 92.95% | 100.00% | 593.45% |
| Return on Assets (ROA) | -49.92% | -29.27% | -42.51% | -20.19% | -119.91% |
| Return on Equity (ROE) | -54.13% | -31.24% | -45.83% | -21.15% | -125.19% |
| Return on Capital Employed (ROCE) | -57.79% | -36.60% | -49.24% | -21.15% | -21.10% |
| Return on Invested Capital (ROIC) | -57.78% | -36.58% | -49.20% | -21.14% | -21.10% |
| Return on Tangible Assets | -49.92% | -29.27% | -42.51% | -20.19% | -119.91% |
| Earnings Yield | -21.49% | -9.60% | -10.85% | -5.51% | -202.22% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.18 | -2.23 | -1.75 | -1.30 | -9.86 |
| Free Cash Flow Per Share | -4.18 | -2.23 | -1.75 | -1.30 | -9.86 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -11470.57 | -398.93 | -176.16 | -313.89 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -20.75% | -8.38% | -8.74% | -6.51% | -49.32% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.66 | -10.41 | -9.22 | -18.15 | -0.49 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.52 | 3.25 | 4.22 | 3.84 | 0.62 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.82 | -11.94 | -11.45 | -15.35 | -2.03 |
| Price-to-Operating Cash Flow Ratio | -4.82 | -11.94 | -11.45 | -15.35 | -2.03 |
| Price-to-Earnings Growth (PEG) Ratio | -0.07 | -0.58 | -0.09 | 0.19 | 0.00 |
| Enterprise Value Multiple | -4.38 | -9.49 | -6.56 | 0.00 | 0.23 |
| Enterprise Value | 728.34M | 764.23M | 489.06M | 506.64M | -11.76M |
| EV to EBITDA | -4.38 | -9.49 | -6.56 | 0.00 | 0.23 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.54 | -10.88 | -8.76 | -11.61 | 0.93 |
| EV to Operating Cash Flow | -4.54 | -10.88 | -8.76 | -11.61 | 0.93 |
| Tangible Book Value Per Share | 7.99 | 8.19 | 4.73 | 5.21 | 32.30 |
| Shareholders’ Equity Per Share | 7.99 | 8.19 | 4.73 | 5.21 | 32.30 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.93 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.97 | 0.87 | 0.81 | 1.18 | 0.24 |
Currency in USD

